Announcement on behalf of OBIGEN that it has filed the application of Phase II human clinical trial for OBI-858 to TFDA

1.Date of occurrence of the event:2024/02/29 2.New drug name or code:OBI-858 Novel Botulinum Neurotoxin 3.Indication: OBI-858, an in-house developed novel botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. Patents for its special molecular weight have been granted in Taiwan, Australia, New Zealand, Japan and Russia. 4.Planned development stages: Phase II, III clinical […]